Skip to main content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer

  • Nabil Mubarak1Email author,
  • Rabab Gaafar2,
  • Samir Shehata3,
  • Tarek Hashem4,
  • Dani Abigeres5,
  • Hamdy A Azim6,
  • Gamal El-Husseiny7,
  • Hamed Al-Husaini8 and
  • Zhixin Liu9
BMC Cancer201212:423

DOI: 10.1186/1471-2407-12-423

Received: 11 January 2012

Accepted: 21 August 2012

Published: 24 September 2012

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
11 Jan 2012 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
26 Apr 2012 Reviewed Reviewer Report - Bryan Schneider
6 May 2012 Reviewed Reviewer Report - Thomas Stinchcombe
8 May 2012 Reviewed Reviewer Report - YoungHak Kim
23 May 2012 Reviewed Reviewer Report - Buelent Polat
2 Aug 2012 Author responded Author comments - Nabil Mobarek
Resubmission - Version 3
2 Aug 2012 Submitted Manuscript version 3
Publishing
21 Aug 2012 Editorially accepted
24 Sep 2012 Article published 10.1186/1471-2407-12-423

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Medical Department, Eli Lilly and Company, Middle East and North Africa
(2)
Medical Oncology Department, National Cancer Institute, Cairo University
(3)
Clinical Oncology Department, Assiut University Cancer Centre
(4)
Clinical Oncology Department, Menoufia University Cancer Centre
(5)
Cancer Center Department, Middle East Institute of Health
(6)
Clinical Oncology Department, Kasr El-Einy Cancer Institute, Cairo University
(7)
Clinical Oncology Department, Faculty of Medicine, Alexandria University
(8)
Oncology Department, King Faisal Specialist Centre and Research Centre
(9)
Statistical Sciences Department, Eli Lilly Australia

Advertisement